Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis either before transplant, or after renal (kidney) transplantation in which there is recurrence of FSGS.

11 Oct 2013

Running a marathon can damage heart muscle for unfit runners

Investigators who studied a group of recreational marathon runners have established that strenuous exercise such as running a marathon can damage the heart muscle. Although they found the effect is temporary and reversible, they warn that these effects are more widespread in less fit distance runners and that recreational distance runners should prepare properly before marathons.

10 Oct 2013

Adempas drug gets FDA approval for treatment of pulmonary hypertension

The U.S. Food and Drug Administration today approved Adempas (riociguat) to treat adults with two forms of pulmonary hypertension. Pulmonary hypertension is caused by abnormally high blood pressure in the arteries of the lungs.

10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Bayer HealthCare receives FDA approval for Adempas tablets

Bayer HealthCare announced today that the United States Food and Drug Administration has approved Adempas (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class; and (ii) the treatment of adults with pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity, improve WHO functional class and delay clinical worsening.

9 Oct 2013

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the first patient has been enrolled in the second clinical trial of Glial Growth Factor 2 (GGF2). This Phase 1b single-infusion trial in people with heart failure will assess tolerability of three dose levels of GGF2, and also includes several explorative measures of efficacy.

9 Oct 2013

Gas transfer excels in predicting mortality in COPD

Researchers say that measuring gas transfer is the most effective way to predict mortality in chronic obstructive pulmonary disease, after finding that it outperformed both spirometry and plethysmography for the purpose.

3 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

OptimEx study may show how to prevent and limit extent of heart failure through exercise

OptimEx, a new 3.5-year study funded by the European Union and coordinated by the Norwegian University of Science and Technology (NTNU), will look at whether exercise could be used both to prevent and treat a specific type of heart failure.

1 Oct 2013

New laser provides better treatment for eye diseases in diabetes patients

A new laser is helping experts at the Truhlsen Eye Institute at the University of Nebraska Medical Center provide better treatment for eye diseases. This advanced laser can prevent blindness for some patients with serious conditions.

24 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Botox Cosmetic receives FDA approval for treatment of crow’s feet lines

The U.S. Food and Drug Administration today approved a new use for Botox Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines, known as crow’s feet, in adults. Botox Cosmetic is the only FDA approved drug treatment option for lateral canthal lines.

12 Sep 2013

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

Avanir Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Wockhardt USA, LLC and Wockhardt Ltd. (collectively, "Wockhardt") to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking approval to market generic versions of Avanir's NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules.

7 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Tactile Medical launches ambulatory device to heal venous leg ulcers

Tactile Medical (formerly Tactile Systems Technology Inc.), a Minneapolis-based developer and provider of home therapy devices, launched a first-of-its-kind ambulatory device for patients with chronic wounds. The ACTitouch Adaptive Compression Therapy system combines two proven therapies - intermittent and sustained compression - in one device to heal venous leg ulcers.

7 Sep 2013

Acute manic episodes linked to increased edema risk

Bipolar disorder patients admitted to hospital with a manic episode are at an increased risk for lower limb edema, compared with their peers with depressive or non-affective psychosis episodes, study findings show.

5 Sep 2013

Edema News and Research

Further Reading

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

Running a marathon can damage heart muscle for unfit runners

Adempas drug gets FDA approval for treatment of pulmonary hypertension

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Bayer HealthCare receives FDA approval for Adempas tablets

Acorda Therapeutics initiates second clinical trial of Glial Growth Factor 2 in heart failure patients

Gas transfer excels in predicting mortality in COPD

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

OptimEx study may show how to prevent and limit extent of heart failure through exercise

New laser provides better treatment for eye diseases in diabetes patients

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Botox Cosmetic receives FDA approval for treatment of crow’s feet lines

Avanir Pharmaceuticals, Wockhardt settle patent litigation related to NUEDEXTA capsules

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Tactile Medical launches ambulatory device to heal venous leg ulcers

Acute manic episodes linked to increased edema risk

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News